Key result
S6K1 inhibitor PF-4708671 reduces ischemia-reperfusion myocardial damage and inhibits necrosis by down-regulating RIP3.
Why the study?
Myocardial ischemia-reperfusion injury is a primary cause of myocardial infarction, and the role and mechanisms of p70 ribosomal S6 kinase (S6K1) in I/R induced necrosis remain unclear.
Does the S6K1-specific inhibitor PF-4708671 reduce myocardial ischemia/reperfusion injury in a rat model?
Does the S6K1-specific inhibitor PF-4708671 reduce myocardial ischemia/reperfusion injury in a rat model?
p-value: p=<0.05
Inhibition of S6K1 with PF-4708671 protects against myocardial ischemia/reperfusion injury in rats by down-regulating RIP3, highlighting a potential therapeutic target.
Hypothesis-generating for S6K1 targeting in I/R injury; prospective trials needed before clinical consideration.
No takes yet. Share an insight, caveat, or question.
Shang et al. (2025) studied Myocardial ischemia-reperfusion injury (n=30). PF-4708671 (S6K1 inhibitor) vs. Saline was evaluated on Myocardial infarct size and tissue necrosis (p=<0.05). Inhibition of S6K1 with PF-4708671 significantly reduced ischemia/reperfusion-induced myocardial tissue damage, improved myocardial function, and inhibited necrosis by down-regulating RIP3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: